Markus K.
- Country
- Germany
- Department
- Zentrum für Neurologie
Research Overview
- Investigation of RO7121932 Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics in Multiple Sclerosis Patients
- Efficacy and Safety of Remibrutinib in Patients with Secondary Progressive Multiple Sclerosis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
- Evaluation of LY3541860 Versus Placebo in Reducing New T1 Gadolinium-Enhancing Lesions in Adults with Relapsing Multiple Sclerosis
Data & Insights
Has run more than one trial at 68 of 234 partner sites.
Specializations
Multiple Sclerosis Specialization
This investigator demonstrates significant expertise in multiple sclerosis (MS) research, with particular focus on both progressive and relapsing forms of the condition.
- Primary Progressive Multiple Sclerosis (PPMS)
- Relapsing Multiple Sclerosis (RMS)
The investigator explores advanced therapeutic approaches for different MS presentations.
Treatment Innovation
Research activities center on evaluating novel therapeutic interventions and investigating higher-dosage protocols of existing treatments for MS patients.
- Advanced dose optimization studies
- Immunogenicity research
- Pharmacokinetic assessments
The investigator's work encompasses both intravenous and subcutaneous administration methods.
Clinical Outcomes
The research focus includes comprehensive evaluation of treatment outcomes in MS patients.
- Disability progression assessment
- MRI brain lesion monitoring
- Safety and tolerability studies
Emphasis is placed on measuring long-term clinical effectiveness and patient safety parameters.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.